01—Abstract
Summary
Summary of the 8-K filed February 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) announced that Yoshiaki Fujimori, a long-serving member of its Board of Directors, will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders.
Mr. Fujimori, who has been on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee, will continue in his roles until the annual meeting. His decision is reportedly not due to any disagreement with the company, which is a positive signal for stability.
This departure represents a change in board composition, and the company's Board and Nominating and Governance Committee will assess the need for any adjustments to the Board's size and makeup following Mr. Fujimori's exit. Investors should monitor any future announcements regarding board appointments or restructuring to understand the company's strategic direction and governance evolution.
02—Key points
Key Highlights
- Yoshiaki Fujimori will not stand for re-election to the Board of Directors at the 2026 Annual Meeting.
- Mr. Fujimori has served as a Director since July 2016.
- He currently serves as the chair of the Risk, Science and Technology Committee.
- Mr. Fujimori will continue in his director and committee roles until the 2026 Annual Meeting.
- The departure is stated to be unrelated to any disagreement with the Company.
- The Board and Nominating and Governance Committee will evaluate future board composition following his departure.
03—Questions
Frequently Asked Questions
Why is Yoshiaki Fujimori not standing for re-election?
Mr. Fujimori has informed Boston Scientific that he will not seek re-election at the 2026 Annual Meeting of Stockholders. The company has stated that this decision is not a result of any disagreement with the Company.
When will Mr. Fujimori's departure from the Board be effective?
Mr. Fujimori will continue to serve as a director and in his committee roles until the 2026 Annual Meeting of Stockholders.
Will the company appoint a new director to replace Mr. Fujimori?
The Board and Nominating and Governance Committee will regularly review the size and composition of the Board and will evaluate whether adding directors following Mr. Fujimori’s departure is in the best interest of the Company. No immediate decision has been made.
Does Mr. Fujimori's departure indicate any issues within Boston Scientific?
The filing explicitly states that Mr. Fujimori's decision is not the result of any disagreement with the Company, suggesting his departure is likely for other reasons, such as personal choice or term limits, and not indicative of internal conflict.
04—Continue